The FDA granted a priority review to capmatinib, a MET inhibitor being analyzed for the first-line treatment of previously treated patients with METex14-mutated advanced NSCLC.
Researchers highlighted the need for patient-reported outcomes data to provide valuable evidence in randomized-controlled trials of cancer treatment.
The results presented in this study indicated that neurosurgeons may need to change how they approach tumor removal and, when safe, include non-contrast-enhancing tumor during resection to achieve maximal resection.
In observing individuals aged 65 and older suffering from a recent nonmetastatic cancer, researchers indicated that there is a need to change attitudes toward aging and older people.
The agency granted full approval to pemetrexed for injection (Pemfexy), a liquid injection and branded alternative to Alimta, for nonsquamous NSCLC.
The authors indicated that prospective clinical trials investigating DTIC-based systemic chemotherapies and liver-directed treatments are necessary to validate their findings.
ASCO named the advance in their annual report, Clinical Cancer Advances: ASCO’s Annual Report on Progress Against Cancer, highlighting novel advances and listing research priorities for the cancer community.
Inconsistencies observed by researchers on these websites indicated that efforts are needed to improve website content and readability.
Delivering the PDA to clients of tobacco quit lines, researchers highlighted the importance of broader dissemination and greater effect of the intervention.
Across all oncologic procedures observed in this study, the robotic approach was found to be most associated with lower out-of-pocket costs.